|  |
|--|
|  |

   

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

 

**FORM 10‐K/ A**

**(Amendment No. 1)**

 

| **☒     ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**     |
|------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                         |
| For the fiscal year ended **December 31, 2019**                                                                              |
|                                                                                                                    |
| OR                                                                                                                           |
|                                                                                                                    |
| **☐     TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** |
|                                                                                                                    |
| For the transition period from ____________ to ___________                                                                   |
|                                                                                                                    |
| Commission File No.******333-204857**                                                                                        |

 

 

| **CURE PHARMACEUTICAL HOLDING CORP.**                  |
|--------------------------------------------------------|
| (Exact name of registrant as specified in its charter) |

 

| **Delaware**                                                 |   | **37-1765151**                       |
|--------------------------------------------------------------|--------|--------------------------------------|
| State or Other Jurisdiction of Incorporation or Organization |   | (I.R.S. Employer Identification No.) |

 

**1620 Beacon Place, Oxnard, California 93033**

(Address of Principal Executive Offices) (Zip Code)

 

Registrant’s telephone number, including area code: **(805) 824-0410**

 

**Securities registered pursuant to Section 12(b) of the Act:**None.

 

**Securities registered pursuant to Section 12(g) of the Act:**

 

| **Title of each class:**       |   | **Trading Symbol** |   | **Name of each exchange on**

**which registered:** |
|--------------------------------|--------|--------------------|--------|-----------------------------------------------------|
| Common stock, par value $0.001 |   | CURR               |   | OTC                                                 |

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐     No ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ☐     No ☒

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒     No ☐

 

 Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒     No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

| Large accelerated filer | ☐ | Accelerated filer         | ☐  |
|-------------------------|---------|---------------------------|---------------|
| Non-accelerated filer   | ☒ | Smaller reporting company | ☒       |
|                         |    | Emerging growth company   | ☒       |

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐     No ☒

 

As of June 30, 2019, the last business day of the registrant’s most recently completed second fiscal quarter, the aggregate market value of its shares held by non-affiliates was approximately $120,175,912, as computed by reference to the closing price of such common stock on the OTC Markets on such date.

 

There were 38,032,793 shares outstanding of the registrant’s common stock, par value $0.001 per share, as of May 11, 2020. The registrant’s common stock is listed on the OTC Markets under the stock symbol “CURR.”

 

| **DOCUMENTS INCORPORATED BY REFERENCE**

** **                                                                            |
|--------------------------------------------------------------------------------------------------------------------------------|
| **The following documents (or parts thereof) are incorporated by reference into the following parts of this Form 10-K: None.** |

 

|  |
|--|
|  |

|   |
|--------|
|        |
|        |
|   |

 

**EXPLANATORY NOTE**

 

This Amendment No. 1 on Form 10-K/A (this “Amendment”) amends the Annual Report on Form 10-K for the fiscal year ended December 31, 2019 originally filed with the Securities and Exchange Commission (the “SEC”) on March 30, 2020 (the “Original Report”) by CURE Pharmaceutical Holding Corp., a Delaware corporation. This Amendment amends the particular sections of Part III, Items 10 and 11 of the Original Report provided below to correct and clarify information relating to the Company’s executive officers and members of the board of directors. Except as stated herein, this Amendment does not amend, modify, or otherwise update any other information in the Original Report. This Amendment does not reflect events that may have occurred after the date the Original Report was filed with the SEC. Accordingly, this Amendment should be read in conjunction with the Original Filing and our other filings with the SEC.

 

In accordance with Rules 12b-15 and 13a-14 under the Exchange Act, the Company has also amended Part IV, Item 15 to include currently dated certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 from the Company’s principal executive officer and principal financial officer. Because no financial statements have been included in this Amendment and this Amendment does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4 and 5 of the certifications have been omitted. Similarly, because no financial statements have been included in this Amendment, certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 have been omitted.

  

Unless otherwise indicated or the context requires otherwise, the words “we,” “us,” “our,” the “Company” or “CURE” refer to CURE Pharmaceutical Holding Corp., a Delaware corporation, its wholly-owned subsidiary, CURE Pharmaceutical Corporation, a California corporation (“CURE Pharmaceutical”) and Chemistry Holdings Inc. and its related subsidiaries recently acquired. 

 

|   |
|--------|
| 2      |
|        |
|   |

 

**PART III**

** **

**ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE**

 

The following table sets forth certain information regarding our Directors and Executive Officers. The age of each Director and Executive Officer listed below is given as of May 1, 2020.

 

| **Name**            | ** ** | **Age** | ** ** | **Position**                                      |
|---------------------|------------|---------|------------|---------------------------------------------------|
| Robert Davidson     |       | 53      |       | Chief Executive Officer, Director                 |
| Michael Redard (1)  |       | 61      |       | Chief Financial Officer                           |
| Jessica Rousset (2) |       | 43      |       | former Chief Operating Officer                    |
| Mark Udell          |       | 43      |       | Chief Accounting Officer, Treasurer and Secretary |
| Vered Gigi Ph.D.    |       | 38      |       | Chief Scientific Officer                          |
| William Yuan        |       | 59      |       | Chairman of the Board of Directors, Director      |
| Gene Salkind, M.D   |       | 64      |       | Director                                          |
| Ruben King-Shaw Jr. |       | 58      |       | Director                                          |
| Joshua Held         |       | 34      |       | Director                                          |
| Lauren Chung Ph.D.  |       | 47      |       | Director                                          |
| Anya Goldin         |       | 57      |       | Director                                          |
| John Bell           |       | 73      |       | Director                                          |
| Charles Berman (3)  |       | 75      |       | former Director                                   |
| Alan Einstein (4)   |       | 53      |       | former Director                                   |
| Alex Katz (5)       |       | 60      |       | former Chief Financial Officer                    |

________ 

| (1) | Mr. Redard was appointed as the Company’s Chief Financial Officer effective May 15, 2019, replacing Alex Katz who resigned as the Company’s Chief Financial Officer on April 5, 2019. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (2) | Mrs. Rousset resigned as the Company’s Chief Operating Officer on May 8, 2020.                                                                                                              |
| (3) | Mr. Berman resigned as a Director of the Company effective January 16, 2019.                                                                                                                      |
| (4) | Mr. Einstein was not reelected to be a Director during the Company’s annual meeting of stockholders on August 6, 2019 and was no longer a Director effective August 6, 2019.                |
| (5) | Mr. Katz resigned as the Company’s Chief Financial Officer on April 5, 2019.                                                                                                                |

 

|   |
|--------|
| 3      |
|        |
|   |

  

*Our Directors*

 

**Robert Davidson – Chief Executive Officer and Director**

 

Robert Davidson has served as a director and Chief Executive Officer since July 2011 and Chairman of our Board until January 2019. Prior to his role at CURE Pharmaceutical, Mr. Davidson served as President and Chief Executive Officer of InnoZen Inc., Chief Executive Officer of Gel Tech LLC, Chief Executive Officer of Bio delivery Technologies Inc., and Director of HealthSport Inc. Mr. Davidson was responsible for the development of several drug delivery technologies and commercial brand extensions. He has worked with brands such as ChlorasepticTM, SuppressTM, as well as PediastripTM, a private label electrolyte oral thin film sold in major drug store chains. Mr. Davidson is also considered an industry expert leader in ODF technology. Mr. Davidson received his B.S. degree with a concentration in Biological Life Sciences from the University of the State of New York, Excelsior College. He has a Masters Certificate in Applied Project Management from Villanova University, Masters of Public Health from American Military University, Virginia and a Masters in Health and Wellness from Liberty University, Virginia. Mr. Davidson is also a Certified Performance Enhancement Specialist and Fitness Nutrition Specialist through the National Academy of Sports Medicine and attended Post-Graduate Studies at the University of Cambridge. Mr. Davidson’s experience as our Chief Executive Officer and Chairman, and his extensive knowledge of ODF and drug delivery technologies qualifies him to serve on our Board.

 

**William Yuan – Director and Chairman of the Board**

** **

William Yuan has served as the Chairman of the Board since January 15, 2019 and as a director since November 7, 2016. Mr. Yuan was most recently Chairman and CEO of Fortress Hill Holdings, an Asian-based investment banking firm. With 23 years in global finance experience, he has served as a key strategist and advisor to international institutions. U.S. companies advised by Mr. Yuan include Amgen Corp., Biogen, GE Capital, Warner Brothers Studios, and Fox News. He has also guided such leading Asian institutions as Sina.com, Shanghai Petrochemicals, Jinlia Pharmaceutical and Tsingtao Beer Corp. In 1995, Mr. Yuan led Merrill Lynch Asset Management Asia, and managed one of the largest pension/retirement funds in the world, with a $488 billion portfolio under his leadership. Simultaneously, he was chairman and portfolio manager of the $1.2 billion AmerAsia Hedge Fund. In 1993, he was the founder and managing director of the Corporate Institutional Services Group at Merrill Lynch Asset Management. Prior to that, Mr. Yuan served as a senior-vice president and co-manager at Morgan Stanley Smith Barney’s Portfolio Management Corporation with dual functions as co-head of the Capital Markets Derivative team, and Chairman of the Technology Investment Management and Executive Policy Committee. He began his finance career at Goldman Sachs in 1983 as an investment banker in Mergers & Acquisitions. Mr. Yuan is a member of the International Who’s Who of Finance, Technology, Media and Telecom. Mr. Yuan holds a Bachelor of Science degree in Economics from Cornell University and attended Harvard University’s John F. Kennedy School as a Mason Fellow. Mr. Yuan’s extensive finance, investment banking and corporate strategy background as well as his experience advising large pharmaceutical companies such as Amgen, Biogen and Jinlia Pharmaceutical qualify him to serve on our Board. Mr. Yuan serves on our Audit, Compensation and Nominating / Corporate Governance Committees.

 

|   |
|--------|
| 4      |
|        |
|   |

  

**Gene Salkind M.D. – Director**

** **

Dr. Gene Salkind has served as a director of the Company since January 15, 2019. Dr. Salkind is board certified in neurological surgery by the American Board of Neurological Surgery and completed various residencies, fellowships and postgraduate training at Abington Memorial hospital, The Graduate Hospital, Veteran’s Administration Hospital, Pennsylvania Hospital, Children’s Hospital of Philadelphia, and the Hospital of the University of Pennsylvania. He received his Medical Degree from Temple University School of Medicine and his Bachelor of Arts from the University of Pennsylvania. He has had numerous faculty, hospital and administrative appointments at virtually every major hospital in the northeastern Philadelphia and surrounding areas. As a prolific pharmaceutical investor, some of Dr. Salkind’s previous successful investments include Intuitive Surgical, Pharmacyclics, which grew from less than $1 per share to subsequently being acquired by Abbvie for $250/share, and Centocor, one of the nation’s largest biotechnology companies, which was acquired by Johnson & Johnson for $4.9 billion in stock. Dr. Salkind currently sits on the board of DermTech, a private company based in San Diego that has become the global leader in non-invasive dermatological molecular diagnostics. Dr. Salkind’s medical background and experience as well as his extensive finance and investing experience qualifies him to serve on our Board.

 

**Ruben King-Shaw, Jr. – Director**

 

Ruben King-Shaw has served as a director of the Company since January 29, 2019. Mr. King-Shaw is currently the President of Steward Health Care Network (SHCN) since June 2018 where he leads the business unit focused on managing integrated, coordinated and community-based health care services delivery in 9 states. He is also the President, since April 2004, of Mansa Equity Partners, Inc. (Mansa), the King-Shaw family’s personal holding company and investment vehicle. In addition to SHCN and Mansa, Mr. King-Shaw has three decades of executive leadership experience in the healthcare technology and private equity sectors and held c-suite positions with leading private companies including Neighborhood Health Partnership, Inc. and JMH Health Plan. He recently served on the board of Atlanta-based Cotiviti Holdings, Inc. and currently serves on the board of privately-held Intelligent Retinal Imaging Systems of Pensacola, FL. Past board service consists of Lead Director of Athena health; Independent Living Systems, of Miami, FL; and WellCare Health Plans, Inc. of Tampa, FL. He served on the Obama Administration's Medicare Program Advisory and Oversight Committee, and he was COO and deputy administrator of the Centers for Medicare and Medicaid Services (CMS) during the administration of President George W. Bush, administering a federal budget of $600 billion. Over the past year, Mr. King-Shaw has provided advice on areas of healthcare policy to the Trump Administration, including CMS and the National Economic Council. Mr. King-Shaw completed his undergraduate studies at Cornell University, earning a Bachelor of Science degree in Industrial and Labor Relations, and earned both a Master of Health Service Administration and a Master of International Business degree from Florida International University. He also completed advanced studies in Corporate Governance at the Harvard Business School. Mr. King-Shaw’s executive experience and administrative expertise in the healthcare field qualifies him to serve on our Board.

 

|   |
|--------|
| 5      |
|        |
|   |

  

**Joshua Held – Director**

 

Joshua Held has served as a director of the Company since May 14, 2019. Mr. Held is currently the President of Form Factory Inc. a wholly owned subsidiary of Acreage Holdings (ARCG.CN) the largest multi-State cannabis operator licensed in 20 States. Since August of 2018, he has led the manufacturing and strategy divisions of Form Factory Inc. Mr. Held is the founder and CEO of Chemistry Holdings, Inc. a formulation technology company that creates innovative, sustainable delivery systems for a variety of industries. Chemistry Holdings was recently acquired by Cure Pharmaceutical. Mr. Held previously founded and was the CEO of Made by Science, rebranded as Form Factory Inc. a private company acquired by Acreage Holdings for $160 Million in December of 2018. Form Factory is at the forefront of the creation of next-generation delivery systems that raise the bar for cannabis product manufacturers and sellers by eliminating common problems in efficacy, formulation, onset, dosage, and labeling. In his prior role as a Vice President of Investments for JP Morgan, Mr. Held managed more than $100 million in investment dollars for high-net-worth individuals and families. He received his Bachelor of Arts from the California State University, Long Beach. He's a licensed real estate broker in California and formally held his Series 7 & 66 licenses. Mr. Held’s accomplishments as the founder of several medical technology companies, including the Company’s acquisition of Chemistry Holdings, qualifies him to serve on our Board.

 

**Lauren Chung, Ph.D. – Director**

 

Dr. Lauren Chung has served as a director of the Company since August 6, 2019. Dr. Chung has 20 years of healthcare investment management and advisory experience. Dr. Chung founded in 2012 MINLEIGH LLC identifying, evaluating and partnering with companies for investments and various strategic, operational, and commercial planning, as well as providing growth capital. Dr. Chung was a Managing Director in Healthcare Research at WestPark Capital, where she joined in 2017. Prior to that she was a Senior Healthcare Equity Analyst at Maxim Group. Previously, Dr. Chung was a Co- Founder of Tokum Capital, a global healthcare fund, which merged with Perella Weinberg Partners. Prior to that, Dr. Chung managed healthcare investment portfolios at RBR Capital, Kingdon Capital, and Pequot Capital. Earlier in her career, Dr. Chung was a recognized research scientist conducting cutting edge research in the field of Alzheimer’s disease and Angelman Syndrome at Massachusetts General Hospital/Harvard Medical School and Boston Children’s Hospital, respectively. Dr. Chung has published many highly regarded peer reviewed scientific journals. Dr. Chung serves as a board member in private healthcare companies. Dr. Chung holds a PhD in Neuropathology from Columbia University-College of Physicians & Surgeons, and a BA with honors in Biochemistry and Economics from Wellesley College. Dr. Chung’s experience in healthcare investments and her academic accomplishments in scientific fields qualifies her to serve on our Board.

 

|   |
|--------|
| 6      |
|        |
|   |

  

**Anya Goldin**

 

Anya Goldin has served as a director of the Company since August 6, 2019. Mrs. Goldin is an accomplished executive with 28 years of experience and demonstrated success across the law, private equity, venture capital, healthcare and telecommunications industries. Since 2014, she has worked as a consultant advising companies on strategic and business issues, complex and cross-border transactions, as well as corporate restructurings and multi-jurisdictional disputes. Anya is also practicing at Nolan Heimann law firm and is teaching a course on International Business Negotiations at the USC’s Gould School of Law. She has co-founded a technology start-up Provenance Laboratories, and engages in entrepreneurial, investment and philanthropic activities. Throughout her executive career, Anya has held leadership positions as a managing partner at Latham & Watkins (17 years), as well as the General Counsel, Vice President and Chair of the Risk Management Committee of a $20-billion London Stock Exchange-listed conglomerate that controlled four other public companies listed on the New York and London Stock Exchanges, as well as a variety of private international assets. Her responsibilities included managing all aspects of the legal and compliance functions of the group. Anya has served on the boards of eight public and private companies in Europe, Russia, India and the UK, and for seven years oversaw international operations of a global regulated private equity fund in her capacity as the Vice Chair of the Board of Directors. Anya is currently on the Advisory Board of a California private equity fund, Lumia Capital, on the Board of Trustees of Westmark School, and on the Board of Berkeley Law Alumni’s L.A. Chapter. Mrs. Goldin is a member of the State Bar of California. She holds a BA in Mass Communications from University of California Berkeley, as well as a JD from the University of California, Berkeley School of Law, graduating in the top ten percent of her class with both degrees. Ms. Goldin’s experience in both business and law, specifically her experience related to start-up and technology companies, qualifies her to serve on our Board.

 

**John Bell**

 

John Bell has served as a director of the Company since November 15, 2019. Mr. Bell is currently the Chairman of Canopy Rivers Corp (TSX: RIV) and Director and Past-Chair of Canopy Growth Corp. (NYSE: CGC). He is Chairman and CEO of Onbelay Capital Inc., a private equity and investment Company based in Cambridge Canada. Mr. Bell also serves as a director of DelMar Pharmaceuticals, Inc. (NASDQ: DMPI) and Chair of the Audit Committee. He has sat on the boards of a number of public, private, not for profit and government boards. He is currently a Governor of the Stratford Festival. He was founder, owner and CEO of Shred-Tech Inc a global Manufacturer of Shredding and recycling equipment and creator of the mobile shredding Industry. He was owner and CEO of Polymer Technologies Inc. a global manufacturer of auto-parts. He was Chairman and principal shareholder of BSM Technologies Inc., a fleet management Company, and was CEO and director of ATS Automation (TSX: ATA-T) with 23 global plants. Mr. Bell is a graduate of Western University Ivey School of Business, a Fellow of the institute of Chartered Accountants of Ontario, a graduate of the Institute of Directors Program of Canada.. Mr. Bell’s financial and executive business experience qualifies him to serve on the Company’s Board of Directors. 

 

|   |
|--------|
| 7      |
|        |
|   |

 

*Our Executive Officers Who are Not Directors*

 

**Michael Redard – Chief Financial Officer**

 

Michael Redard has served as the Chief Financial Officer of CURE Pharmaceutical since May 2019. Mr. Redard has over 30 years of experience in financial operations, strategic planning and capital markets across a broad range of industries including medical devices, healthcare, consumer and industrial products, and manufacturing. Prior to CURE Mr. Redard served as CFO of Casa Pacifica, a California based behavioral health services provider. Before that he held CFO, Vice President and General Manager positions with several venture and private equity backed companies including Inogen, Medical Analysis Systems (acquired by Thermo Fisher Scientific), CDTi Advanced Materials, and Abrisa Technologies. Earlier experience includes management roles with Pepsi and in public accounting. He is a CPA (inactive) and received his B.S. in Business Administration from California Polytechnic State University, San Luis Obispo.

 

**Jessica Rousset – Chief Operating Officer**

 

Jessica Rousset has served as the Company’s Chief Operating Officer since January 22, 2018. She previously served since March 15, 2017 as the Company’s Chief Business Officer, oversees operations and drives corporate strategy and growth. Mrs. Rousset previously served as Head of Innovation at Children’s Hospital Los Angeles, where over a ten-year period from 2006 to November 2016, she helped launch both therapeutic and medical device companies and founded and operated a national pediatric technology accelerator. Prior to that, Mrs. Rousset held positions at The Scripps Research Institute and GlaxoSmithKline Biologicals in laboratory, clinical research and business development roles. She is a seasoned business development and commercialization leader, expert in bridging corporate, academic and governmental interests toward the common goal of improving patient’s lives. She brings more than fifteen years of experience fostering innovation in large organizations and advising start-ups to bring novel healthcare solutions to market and into clinical use. She trained as a biochemical engineer at the Institut National des Sciences Appliquées in Lyon, France. Mrs. Rousset resigned as the Company’s Chief Operating Officer on May 8, 2020.

 

|   |
|--------|
| 8      |
|        |
|   |

  

**Mark Udell – Chief Accounting Officer, Treasurer and Secretary**

 

Mark Udell has served as the Chief Accounting Officer since November 2018 and as Treasurer and Secretary of CURE Pharmaceutical since July 2011. He is a Certified Public Accountant with over 17 years of experience in finance and accounting. Prior to joining the Company in 2011, Mr. Udell served as InnoZen, Inc.’s Chief Accounting Officer and Controller and was responsible for establishing, monitoring and enforcing policies and procedures for the company as well as conducting audits and working with external auditors. While working at CURE and InnoZen, Inc., Mr. Udell gained valuable knowledge in the drug delivery industry and is a key contributor in the development and commercialization of various drug delivery technologies. He has also held the position as Auditing Manager at Green Hasson & Janks, LLP in Los Angeles. Mr. Udell received his B.A. in Business Economics with a concentration in accounting from the University of California, Santa Barbara.

 

**Vered Gigi Ph.D. – Chief Scientific Officer**

 

Dr. Vered Gigi has served as the Chief Scientific Officer since October 1, 2019. She previously served since January 22, 2018 as the Company’s VP of Strategy and Business Development a role in which she governed and aligned CURE’s strategy to its scientific operations to deliver sustained growth and diversified revenue from CURE’s nutraceutical and pharmaceutical pipelines. Before joining CURE, Dr. Gigi served as a project leader at The Boston Consulting Group from July 2014 to January 2018 working with global biopharma and medtech companies focusing on corporate and network strategy, operations and marketing. Dr. Gigi graduated from Tel-Aviv University in Israel with a bachelor’s degree and a master’s degree investigating immunotherapy and stem cell. She then went on to earn her Ph.D. in Immunology from the University of Pennsylvania, focusing her studies on DNA repair mechanisms and genome sequencing.

 

*Board of Directors*

 

Our Board of Directors currently consists of eight members. All directors hold office until the next annual meeting of stockholders. At each annual meeting of stockholders, the successors to directors whose terms then expire are elected to serve from the time of election and qualification until the next annual meeting following election. 

 

Management has been delegated the responsibility for meeting defined corporate objectives, implementing approved strategic and operating plans, carrying on our business in the ordinary course, managing cash flow, evaluating new business opportunities, recruiting staff and complying with applicable regulatory requirements. The Board of Directors exercises its supervision over management by reviewing and approving long-term strategic, business and capital plans, material contracts and business transactions, and all debt and equity financing transactions and stock issuances.

 

|   |
|--------|
| 9      |
|        |
|   |

  

**ITEM 11. EXECUTIVE COMPENSATION**

 

            The following table sets forth total compensation earned by our named executive officers, who are comprised of our principal executive officer and our next two most highly compensated executive officers for the years ended December 31, 2019 and 2018.

 

*Summary Compensation Table*

 

| **Name and Principal Position**         | ** ** | **Year** | ** ** | **Salary**

**($)** | ** ** | ** ** | **Bonus**

**($)** | ** ** | ** ** | **Stock**

**Awards****(1)**

**($)** | ** ** | ** ** | **Option Awards****(2)**

**($)** | ** ** | ** ** | **All Other**

**Compensation**

**($)** | ** ** | ** ** | **Total**

**($)** |   |
|-----------------------------------------|------------|----------|------------|---------------------|------------|------------|--------------------|------------|------------|---------------------------------------|------------|------------|-----------------------------------|------------|------------|------------------------------------------|------------|------------|--------------------|--------|
| Robert Davidson(3),                     |       | 2019     |       |                | 196,667    |       |               |       | -          |                                  |       |       | -                                 |       |       |                                     | 736,029    |       |               |   | - |   |   |   | 932,696 |   |
| *Chief Executive Officer*               |       | 2018     |       |                | 175,833    |       |               |       | -          |                                  |       |       | 23,125                            |       |       |                                     | 251,558    |       |               |   | 15,082 |   |   |   | 465,598 |   |
|                                    |       |     |       |                |       |       |               |       |       |                                  |       |       |                              |       |       |                                     |       |       |               |   |   |   |   |   |   |   |
| Michael Redard,                         |       | 2019     |       |                | 106,893    |       |               |       | -          |                                  |       |       | -                                 |       |       |                                     | 925,289    |       |               |   | -- |   |   |   | 1,032,182 |   |
| *Chief Financial Officer*               |       | 2018     |       |                | -          |       |               |       | -          |                                  |       |       | -                                 |       |       |                                     | -          |       |               |   | - |   |   |   | - |   |
|                                    |       |     |       |                |       |       |               |       |       |                                  |       |       |                              |       |       |                                     |       |       |               |   |   |   |   |   |   |   |
| Jessica Rousset(4),                     |       | 2019     |       |                | 180,000    |       |               |       | -          |                                  |       |       | -                                 |       |       |                                     | -          |       |               |   | - |   |   |   | 180,000 |   |
| *Chief Operating Officer*               |       | 2018     |       |                | 180,000    |       |               |       | -          |                                  |       |       | 29,600                            |       |       |                                     | 208,268    |       |               |   | 19,284 |   |   |   | 437,152 |   |
|                                    |       |     |       |                |       |       |               |       |       |                                  |       |       |                              |       |       |                                     |       |       |               |   |   |   |   |   |   |   |
| Mark Udell, *Chief Accounting Officer,* |       | 2019     |       |                | 134,413    |       |               |       | -          |                                  |       |       | -                                 |       |       |                                     | -          |       |               |   | - |   |   |   | 134,413 |   |
| *Treasurer and Secretary*               |       | 2018     |       |                | 115,000    |       |               |       | -          |                                  |       |       | -                                 |       |       |                                     | 89,258     |       |               |   | - |   |   |   | 204,258 |   |

__________ 

| (1) | Represents the grant date fair value of restricted stock units calculated in accordance with FASB ASC Topic 718 calculated based on closing price of our common stock on the day of the grant date of the restricted stock units multiplied by the number of shares granted. Restricted stock units are subject to time-based vesting as described below. These amounts do not represent cash payments or proceeds actually received by the directors and the actual values they realize may be materially different from these reported amounts upon their sale of the underlying shares. For fair value assumptions refer to Note 14 to our financial statements included in our Annual Report on Form 10-K.                                                                                                                                                                                                                                                                                                                                                                        |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (2) | In accordance with SEC rules, the amounts in this column reflect the fair value on the grant date of the option awards granted to the named executive officer, calculated in accordance with ASC Topic 718. Stock options were valued using the Black-Scholes model. The grant-date fair value does not necessarily reflect the value of shares which may be received in the future with respect to these awards. The grant-date fair value of the stock options in this column is a non-cash expense for the Company that reflects the fair value of the stock options on the grant date and therefore does not affect our cash balance. The fair value of the stock options will likely vary from the actual value the holder receives because the actual value depends on the number of options exercised and the market price of our common stock on the date of exercise. For a discussion of the assumptions made in the valuation of the stock options, see Note 14 (Stock Incentive Plans) to our financial statements, which are included in our Annual Report on Form 10-K. |
| (3) | Robert Davidson is also a member of our Board of Directors, but does not receive any compensation for his service as a director.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| (4) | Jessica Rousset resigned as the Company’s Chief Operating Officer on May 8, 2020.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

 

|   |
|--------|
| 10     |
|        |
|   |

  

*Outstanding Equity Awards at December 31, 2019*

 

The following table sets forth information regarding the outstanding equity awards held by our named executive officers as of December 31, 2019:

 

| **Option Awards(1)**                                      |   |
|-----------------------------------------------------------|--------|
|                                                      |   |   |   | **Vesting **  |   | **Number of Securities Underlying Unexercised Options** |   |   | **Option Exercise **  |   |   | **Option**

** Expiration** |   |
| **Name**                                                  |   | **Grant Date** |   | **Start Date** |   | **Exercisable (#)** |   |   | **Unexercisable (#)** |   |   | **Price****($)** |   |   | **Date** |   |
| Robert Davidson                                           |   | 04/06/2018 |   | 11/07/2016 |   |   | 265,500 |   |   |   | 88,500 | (2) |   | $ | 0.74 |   |   | 04/06/2028 |   |
| *Chief Executive Officer*                            |   | 05/07/2018 |   | 05/07/2018 |   |   | 25,781 |   |   |   | 42,969 | (2) |   | $ | 0.61 |   |   | 05/07/2028 |   |
|                                                      |   | 04/11/2019 |   | 04/11/2019 |   |   | 28,125 |   |   |   | 196,875 | (2) |   | $ | 3.40 |   |   | 04/11/2029 |   |
|                                                      |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Michael Redard                                            |   | 05/30/2019 |   | 05/30/2019 |   |   | 50,000 |   |   |   | - |   |   | $ | 4.01 |   |   | 05/30/2029 |   |
| *Chief Financial Officer*                            |   | 05/30/2019 |   | 05/15/2019 |   |   | 25,000 |   |   |   | 175,000 | (2) |   | $ | 4.01 |   |   | 05/30/2029 |   |
|                                                      |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Jessica Rousset(3)                                        |   | 04/06/2018 |   | 03/15/2017 |   |   | 199,375 |   |   |   | 90,625 | (2) |   | $ | 0.74 |   |   | 04/06/2028 |   |
| *Chief Operating Officer*                            |   | 05/07/2018 |   | 05/07/2018 |   |   | 22,500 |   |   |   | 37,500 | (2) |   | $ | 0.61 |   |   | 05/07/2028 |   |
|                                                      |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Mark Udell                                                |   | 04/06/2018 |   | 01/01/2018 |   |   | 65,625 |   |   |   | 84,375 | (2) |   | $ | 0.74 |   |   | 04/06/2028 |   |
| *Chief Accounting Officer, Treasurer, and Secretary* |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |

________ 

| (1)    | All option awards set forth in this table have been granted under the 2017 Equity Incentive Plan.                                                                                                                                                                           |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                        |
| (2)    | 1/16 of the shares subject to the option will vest quarterly, beginning on the first quarter anniversary of the vesting start date, subject to continuous service through each vesting date.                                                                                |
|   |                                                                                                                                                                                                                                                                        |
| (3)    | In connection with Mrs. Rousset’s resignation, effective May 8, 2020, the Company has agreed to accelerate the vesting of each equity award held by her to the extent the award would have vested had she remained employed for six months following her resignation. |

 

|   |
|--------|
| 11     |
|        |
|   |

  

****PART IV****

 

**Item 15. Exhibits and Financial Statement Schedules.**

 

Part IV of our Original Report is hereby amended solely to add the following Exhibits required to be filed in connection with this Amendment.

 

**EXHIBIT INDEX**

**** 

| **Number** | **    ** | **Description**                                                                                         |
|------------|------------------------------|---------------------------------------------------------------------------------------------------------|
| 31.1       |                         | Certifications of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
|       |                         |                                                                                                    |
| 31.2       |                         | Certifications of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |

  

|   |
|--------|
| 12     |
|        |
|   |

   

**SIGNATURES**

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

|                     | **CURE PHARMACEUTICAL HOLDING CORP.** |                               |
|---------------------|---------------------------------------|-------------------------------|
|                     |                                       |                               |   |
| Dated: May 15, 2020 | By:                                   | */s/ Robert Davidson*         |  |
|                     |                                  | Robert Davidson               |  |
|                     |                                  | Chief Executive Officer       |  |
|                     |                                  | (Principal Executive Officer) |  |

 

|   |
|--------|
| 13     |